Immunic, Inc. (IMUX)
NASDAQ: IMUX · Real-Time Price · USD
12.77
-1.66 (-11.50%)
At close: Jun 5, 2026, 4:00 PM EDT
12.78
+0.01 (0.08%)
After-hours: Jun 5, 2026, 7:43 PM EDT
Immunic Employees
Immunic had 92 employees as of December 31, 2025. The number of employees increased by 1 or 1.10% compared to the previous year.
Employees
92
Change
1
Growth
1.10%
Revenue / Employee
n/a
Profits / Employee
-$1,133,554
Market Cap
173.95M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 92 | 1 | 1.10% |
| Sep 30, 2025 | 90 | 5 | 5.88% |
| Jun 30, 2025 | 90 | 5 | 5.88% |
| Mar 31, 2025 | 90 | 10 | 12.50% |
| Dec 31, 2024 | 91 | 14 | 18.18% |
| Sep 30, 2024 | 85 | 5 | 6.25% |
| Jun 30, 2024 | 85 | 10 | 13.33% |
| Mar 31, 2024 | 80 | 7 | 9.59% |
| Dec 31, 2023 | 77 | 11 | 16.67% |
| Sep 30, 2023 | 80 | 15 | 23.08% |
| Jun 30, 2023 | 75 | 15 | 25.00% |
| Mar 31, 2023 | 73 | 18 | 32.73% |
| Dec 31, 2022 | 66 | 11 | 20.00% |
| Sep 30, 2022 | 65 | 13 | 25.00% |
| Jun 30, 2022 | 60 | 15 | 33.33% |
| Mar 31, 2022 | 55 | 15 | 37.50% |
| Dec 31, 2021 | 55 | 27 | 96.43% |
| Sep 30, 2021 | 52 | 24 | 85.71% |
| Jun 30, 2021 | 45 | - | - |
| Mar 31, 2021 | 40 | 14 | 53.85% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Karyopharm Therapeutics | 228 |
| Tonix Pharmaceuticals Holding | 142 |
| MediWound | 121 |
| Nkarta | 108 |
| Alector | 103 |
| Caribou Biosciences | 97 |
| Cartesian Therapeutics | 75 |
| Enlivex | 34 |
IMUX News
- 7 days ago - Immunic Proxy statement: Proxy filing - Filings
- 8 days ago - Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis - PRNewsWire
- 9 days ago - Immunic CEO Daniel Vitt to step down, Erik Lundgren to succeed - TheFly
- 9 days ago - Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer - PRNewsWire
- 14 days ago - B. Riley cuts Immunic target, sees ‘compelling entry point’ - TheFly
- 17 days ago - Immunic appoints Michael Bonney as chair - TheFly
- 17 days ago - Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors - PRNewsWire
- 22 days ago - Immunic price target lowered to $19 from $26 at Roth Capital - TheFly